{"disease":{"id":"adjuvant-therapy-in-patients-with-hepatocellular-carcinoma-hcc-at-high-risk-of-recurrence-after-curative-resection-or-ablation","name":"adjuvant therapy in patients with hepatocellular carcinoma hcc at high risk of recurrence after curative resection or ablation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05367687","title":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}